세계의 방사선 치료학 시장 보고서(2025년)
Radiotheranostics Global Market Report 2025
상품코드 : 1824451
리서치사 : The Business Research Company
발행일 : On Demand Report
페이지 정보 : 영문 250 Pages
 라이선스 & 가격 (부가세 별도)
US $ 4,490 ₩ 6,448,000
PDF (Single User License) help
PDF 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.
US $ 6,490 ₩ 9,320,000
PDF (Site License) help
PDF 보고서를 동일 사업장의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.
US $ 8,490 ₩ 12,193,000
PDF (Enterprise License) help
PDF 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.


ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
ㅁ 보고서에 따라 최신 정보로 업데이트하여 보내드립니다. 배송기일은 문의해 주시기 바랍니다.

한글목차

방사선 치료학 시장 규모는 향후 수년간 급성장할 것으로 전망됩니다. 2029년에는 복합 연간 성장률(CAGR) 13.8%로 168억 7,000만 달러로 성장할 것으로 예상됩니다. 예측 기간의 성장은 표적 암 치료의 진보, 종양학 연구의 확대, 만성 질환 증가, 세라노스틱 응용의 성장에 기인하고 있습니다. 예측 기간의 주요 동향은 세라노스틱 방사성 의약품 개발, 종양학 이외의 용도 확대, 개별화 방사성 의약품, 방사선 치료학의 나노기술, 규제 이동, 표준화 등을 포함합니다.

향후 5년간의 성장률 13.8%라는 예측은 전회 예측으로부터 0.2%의 소폭 감소를 반영하고 있습니다. 이 감소는 주로 미국과 다른 국가 간의 관세의 영향 때문입니다. 관세의 부과는 네덜란드나 한국에서 수입되는 luorodeoxyglucose-Positron Emission Tomography-Positron Emission Tomography 방사성 트레이서나 서노스틱스 프로브의 비용을 상승시킴으로써, 미국공급 체인을 혼란시킬 가능성이 있어, 암 표적 치료를 제한해, 화상 진단의 부담을 증가시킬 가능성. 또한 상호관세와 무역의 긴장과 한계 증가로 인한 세계경제와 무역에 대한 악영향으로 인해 그 영향이 더욱 광범위해질 것으로 보입니다.

암 이환율의 상승은 향후 방사선 치료학 시장의 성장을 이끌 것으로 예측됩니다. 암은 신체의 특정 세포가 통제 불능으로 개발되어 다른 부위로 전이하는 것을 특징으로 합니다. 방사선 치료학 약물은 진단용 및 치료용 방사성 핵종 프로브를 쌍으로 만들어 개별화된 의료 개념을 제공하는 종양학에서 널리 사용됩니다. 이 프로브는 치료 효과를 높이고 임상 결과를 개선하기 위해 환자의 특정 상태에 맞게 특정(일반적으로 암성) 세포를 선택적이고 표적으로 감지하고 치료할 수 있습니다. 예를 들어 2024년 1월 미국을 거점으로 하는 암 관련 비영리단체인 미국암협회(American Cancer Society)는 암 환자수가 2023년 195만 8,310명에서 200만 1,140명으로 증가해 2.19% 증가했습니다. 이와 같이, 암 이환율 증가가 방사선 치료학 시장을 견인하고 있습니다.

목차

제1장 주요 요약

제2장 시장 특징

제3장 시장 동향과 전략

제4장 시장 : 금리, 인플레이션, 지정학, 무역전쟁과 관세, 그리고 코로나 및 회복이 시장에 미치는 영향을 포함한 거시경제 시나리오

제5장 세계의 성장 분석과 전략 분석 프레임워크

제6장 시장 세분화

제7장 지역별/국가별 분석

제8장 아시아태평양 시장

제9장 중국 시장

제10장 인도 시장

제11장 일본 시장

제12장 호주 시장

제13장 인도네시아 시장

제14장 한국 시장

제15장 서유럽 시장

제16장 영국 시장

제17장 독일 시장

제18장 프랑스 시장

제19장 이탈리아 시장

제20장 스페인 시장

제21장 동유럽 시장

제22장 러시아 시장

제23장 북미 시장

제24장 미국 시장

제25장 캐나다 시장

제26장 남미 시장

제27장 브라질 시장

제28장 중동 시장

제29장 아프리카 시장

제30장 경쟁 구도와 기업 프로파일

제31장 기타 주요 기업 및 혁신 기업

제32장 세계 시장 경쟁 벤치마킹과 대시보드

제33장 주요 인수합병(M&A)

제34장 최근 시장 동향

제35장 시장의 잠재력이 높은 국가, 부문, 전략

제36장 부록

SHW
영문 목차

영문목차

Radiotheranostics refers to a medical approach that combines diagnoses and treatments using imaging methods with radioactive substances to precisely identify specific targets within the body. This method is employed for delivering targeted radiation therapy to defined locations, enabling precise and tailored cancer treatment while minimizing damage to healthy tissues. This approach enhances treatment outcomes and improves patient care.

The primary radiotheranostics radioisotopes include technetium-99, gallium-68, iodine-131, iodine-123, fludeoxyglucose-18F, yttrium-90, lutetium (Lu) 177, copper (Cu) 67, copper (Cu) 64, and others. Technetium (Tc) is a silver-gray radioactive metal that occurs naturally at extremely low levels in the earth's crust but is predominantly man-made. It is used for skeletal and heart muscle scans and imaging of various organs such as the brain, thyroid, lungs, liver, spleen, kidneys, gall bladder, bone marrow, salivary and lacrimal glands, as well as in some specialized medical research. The different approaches include targeted therapeutic and targeted diagnostic applications in both oncology and non-oncology. The end users of this technology include hospitals and clinics, pharmaceutical and biotechnology companies, and others.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report's Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The sharp rise in U.S. tariffs and the resulting trade tensions in spring 2025 are having a significant impact on the healthcare sector, especially in the supply of essential medical devices, diagnostic equipment, and pharmaceuticals. Hospitals and healthcare providers are grappling with higher costs for imported surgical tools, imaging systems, and consumables like syringes and catheters, many of which have limited domestic substitutes. These escalating expenses are putting pressure on healthcare budgets, prompting some providers to delay equipment upgrades or pass increased costs on to patients. Furthermore, tariffs on raw materials and components are disrupting the manufacturing of vital drugs and devices, leading to supply chain delays. In response, the industry is adopting diversified sourcing strategies, expanding local production where feasible, and pushing for tariff exemptions on critical medical products.

The radio theranostics market research report is one of a series of new reports from The Business Research Company that provides radio theranostics market statistics, including radio theranostics industry global market size, regional shares, competitors with a radio theranostics market share, detailed radio theranostics market segments, market trends, and opportunities, and any further data you may need to thrive in the radio theranostics industry. This radio theranostics market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The radiotheranostics market size has grown rapidly in recent years. It will grow from $8.79 billion in 2024 to $10.05 billion in 2025 at a compound annual growth rate (CAGR) of 14.4%. The growth in the historic period can be attributed to advancements in nuclear medicine, a rise in cancer cases, personalized medicine development, advances in radiopharmaceuticals, regulatory approvals and standards.

The radiotheranostics market size is expected to see rapid growth in the next few years. It will grow to $16.87 billion in 2029 at a compound annual growth rate (CAGR) of 13.8%. The growth in the forecast period can be attributed to advancements in targeted cancer therapies, expansion in oncology research, rise in chronic diseases, and growth in theranostic applications. Major trends in the forecast period include theranostic radiopharmaceutical development, expanding applications beyond oncology, personalized radiopharmaceuticals, nanotechnology in radiotheranostics, regulatory shifts and standardization.

The forecast of 13.8% growth over the next five years reflects a slight reduction of 0.2% from the previous projection. This reduction is primarily due to the impact of tariffs between the US and other countries. The imposition of tariffs may disrupt U.S. supply chains by increasing costs for luorodeoxyglucose-Positron Emission Tomography -Positron Emission Tomography radiotracers and theranostic probes imported from the Netherlands and South Korea, potentially limiting targeted oncology therapies and raising diagnostic imaging burdens. The effect will also be felt more widely due to reciprocal tariffs and the negative effect on the global economy and trade due to increased trade tensions and restrictions.

The rising incidence of cancer is anticipated to drive the growth of the radiotheranostics market in the future. Cancer is characterized by the uncontrolled development of certain cells in the body that spread to other areas. Radiotheranostics medications are widely used in oncology to provide the concept of personalized medicine through paired diagnostic and therapeutic radionuclide probes. These probes enable selective and targeted detection and treatment of specific (typically cancerous) cells, tailored to the patient's specific condition to enhance treatment efficacy and improve clinical outcomes. For example, in January 2024, the American Cancer Society, a US-based nonprofit organization focused on cancer advocacy, reported an increase in cancer cases to 2,001,140, up from 1,958,310 in 2023, marking a growth of 2.19%. Thus, the increasing prevalence of cancer is propelling the radiotheranostics market.

The increasing adoption of personalized medicine is poised to contribute to the growth of the radiotheranostics market. Personalized medicine, an innovative healthcare approach tailoring medical treatments to individual patient characteristics, is facilitated by radiotheranostics. This approach, utilizing specific radiopharmaceuticals, enables the identification of individualized molecular targets, allowing for precise diagnosis and tailored therapeutic interventions based on the patient's unique characteristics. In 2022, the Food and Drug Administration's Center for Drug Evaluation and Research (CDER) approved 37 new molecular entities (NMEs), with approximately 34% classified as personalized medicines, according to the Personalized Medicine Coalition. The increasing adoption of personalized medicine is a key driver for the growth of the radiotheranostics market.

An emerging trend in the radiotheranostics market is the focus on product innovations. Major companies are directing their efforts towards creating innovative products to solidify their market positions. For instance, Advanced Cyclotron Systems Inc., a Canada-based company specializing in cyclotrons for medical isotope production, introduced TR-ALPHA in May 2023. This innovation is designed for the production of alpha-emitting radioisotopes used in cancer treatment. TR-ALPHA addresses market demands for a low-cost cyclotron capable of producing substantial amounts of Astatine-211, a promising alpha-emitting radioisotope. This product is smaller, more cost-effective, and easier to operate compared to previous cyclotron models, making it an ideal solution for efficiently producing therapeutic alpha-emitting radioisotopes.

Major companies in the radiotheranostics market are forming strategic partnerships to develop new products and strengthen their market positions. Collaborations and partnerships in this market facilitate the pooling of resources, expertise, and research efforts, accelerating the development, commercialization, and widespread adoption of advanced diagnostic and therapeutic solutions. In April 2022, Ion Beam Applications partnered with SCK CEN to advance the production of the radioisotope Actinium-225, a crucial element in cancer treatment. This collaboration aims to establish a state-of-the-art production facility in Mol, Belgium, combining expertise in particle accelerators and the provision of rare raw materials. Such collaborations are crucial for making radiotheranostic solutions commercially viable for treating various cancers with enhanced precision.

In June 2023, Ariceum Therapeutics GmbH, a Germany-based radiopharmaceutical company, acquired Theragnostics Ltd. for $41.5 million. This strategic acquisition is intended to broaden Ariceum's portfolio of therapeutic and diagnostic assets in late preclinical and early clinical development and expand its operations in the US. Theragnostics Ltd., a US-based radiopharmaceutical company, specializes in offering radio-theranostic solutions.

Major companies operating in the radiotheranostics market include Lantheus Holdings Inc., Cardinal Health Inc., GE Healthcare Inc., Bayer AG, Novartis AG, Siemens Healthineers, Orano Med, Curium SAS, IBA Molecular, The Eckert & Ziegler Group, Advanced Accelerator Applications (AAA), Telix Pharmaceuticals Limited., Abdera Therapeutics, Blue Earth Diagnostics, Sirtex Medical Limited, Y-mAbs Therapeutics Inc., ITM Radiopharma, NorthStar Medical Radioisotopes LLC, Trasis S.A., Molecular Targeting Technologies Inc., RadioMedix Inc, Clarity Pharmaceuticals, Actinium Pharmaceuticals Inc., Navidea Biopharmaceuticals Inc.

North America was the largest region in the radiotheranostics market in 2024. The regions covered in the radiotheranostics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the radiotheranostics market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The radiotheranostics market consists of sales of iodine-125, radium-223 (223Ra), astatin-211 (211At), actinium-225 (225Ac), lead-212 (212Pb), bismuth-212 (212Bi), thorium-227, strontium-89 (89Sr), rhenium-188 (188Re), and samarium-153 (153Sm). Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Radiotheranostics Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on radiotheranostics market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

Where is the largest and fastest growing market for radiotheranostics ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The radiotheranostics market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.

Scope

Table of Contents

1. Executive Summary

2. Radiotheranostics Market Characteristics

3. Radiotheranostics Market Trends And Strategies

4. Radiotheranostics Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

5. Global Radiotheranostics Growth Analysis And Strategic Analysis Framework

6. Radiotheranostics Market Segmentation

7. Radiotheranostics Market Regional And Country Analysis

8. Asia-Pacific Radiotheranostics Market

9. China Radiotheranostics Market

10. India Radiotheranostics Market

11. Japan Radiotheranostics Market

12. Australia Radiotheranostics Market

13. Indonesia Radiotheranostics Market

14. South Korea Radiotheranostics Market

15. Western Europe Radiotheranostics Market

16. UK Radiotheranostics Market

17. Germany Radiotheranostics Market

18. France Radiotheranostics Market

19. Italy Radiotheranostics Market

20. Spain Radiotheranostics Market

21. Eastern Europe Radiotheranostics Market

22. Russia Radiotheranostics Market

23. North America Radiotheranostics Market

24. USA Radiotheranostics Market

25. Canada Radiotheranostics Market

26. South America Radiotheranostics Market

27. Brazil Radiotheranostics Market

28. Middle East Radiotheranostics Market

29. Africa Radiotheranostics Market

30. Radiotheranostics Market Competitive Landscape And Company Profiles

31. Radiotheranostics Market Other Major And Innovative Companies

32. Global Radiotheranostics Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Radiotheranostics Market

34. Recent Developments In The Radiotheranostics Market

35. Radiotheranostics Market High Potential Countries, Segments and Strategies

36. Appendix

(주)글로벌인포메이션 02-2025-2992 kr-info@giikorea.co.kr
ⓒ Copyright Global Information, Inc. All rights reserved.
PC버전 보기